Results 181 to 190 of about 31,673 (300)

Temporal profiling of M‐TEER‐related complications

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Transcatheter edge‐to‐edge repair of the mitral valve (M‐TEER) is known for its low complication rates. However, the optimal level and duration of post‐procedural care remain unclear. This study aimed to identify the specific timeframe of post‐procedural complications following M‐TEER.
Jafer Haschemi   +8 more
wiley   +1 more source

Surgical resection combined with perioperative chemotherapy for a patient with locally recurrent, previously stage IV thymic small‐cell carcinoma: A case report

open access: yesThoracic Cancer, Volume 13, Issue 23, Page 3415-3419, December 2022., 2022
We present the case of an elderly man with thymic small‐cell carcinoma, a thymic neuroendocrine tumor, where multidisciplinary treatment, including chemotherapy comprising carboplatin and etoposide, and salvage surgery, was considered effective. Chest computed tomography scans show that 4 months after initiation of chemotherapy, the tumor and pleural ...
Junki Terada   +10 more
wiley   +1 more source

Surgical Management of Echinococcal Cysts of the Heart and Pericardium [PDF]

open access: bronze, 1963
Alfred Heilbrunn   +2 more
openalex   +1 more source

Prevalence and prognostic value of different iron deficiency definitions in light chain cardiac amyloidosis patients

open access: yesESC Heart Failure, EarlyView.
Non‐scaled Venn diagram of iron deficiency (ID) according to various definitions and associated outcomes. The prevalence of iron deficiency was high, irrespective of the definition applied. ID defined by TSAT <20% or serum iron <13 μmol/L, rather than the guideline definition, was associated with worse outcomes.
Xinqing Li   +7 more
wiley   +1 more source

Prognostic factors and genetic markers in thymic epithelial tumors: A narrative review

open access: yesThoracic Cancer, Volume 13, Issue 23, Page 3242-3249, December 2022., 2022
The aim of this review article is to discuss the different prognostic factors and genetic markers of TET and to point out discrepancies and similarities among the available literature (concerning prognostic factors) and more importantly to demonstrate the genetic pathways that could be the basis of a development of new targeted therapies.
Apostolos C. Agrafiotis   +5 more
wiley   +1 more source

Immune cell dynamics in heart failure: implicated mechanisms and therapeutic targets

open access: yesESC Heart Failure, EarlyView.
Abstract The relationship between heart failure (HF) and immune activation has garnered significant interest. Studies highlight the critical role of inflammation in HF, affecting cardiac structure and function. Despite promising anti‐inflammatory therapies, clinical trials have faced challenges, indicating an incomplete understanding of immune ...
Gen Li, Wu He, Dao Wen Wang
wiley   +1 more source

Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003)

open access: yesThoracic Cancer, Volume 14, Issue 1, Page 105-107, January 2023., 2023
Recently, the addition of anti‐programmed cell death‐ligand 1 (PD‐L1) monoclonal antibodies, including durvalumab and atezolizumab to platinum‐based chemotherapy, has demonstrated clinical benefits in patients with untreated advanced small cell lung cancer (SCLC). However, these clinical trials comprised small populations of elderly patients with SCLC.
Hidenobu Ishii   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy